Pharmaceutical Product Monograph: Esomeprazole & Domperidone FDC
In the pharmaceutical industry, the combination of Esomeprazole and Domperidone is one of the most widely prescribed Fixed-Dose Combinations (FDCs) for upper gastrointestinal disorders. As a pharmacist and manufacturer, I classify this as a “Synergistic Acid-Prokinetic” therapy. It is technically superior to a single PPI because it addresses both the chemical (acid) and mechanical (movement) failures of the digestive system.
At your WHO-GMP facility in Mumbai, this Sustained-Release (SR) capsule is a flagship SKU for Gastroenterology portfolios. It is specifically designed to overcome “Refractory GERD”—where acid suppression alone isn’t enough to stop symptoms.
Therapeutic Profile: Primary Indications
This combination is indicated for acid-peptic disorders complicated by nausea or slow stomach emptying.
| Component | Technical Role | Clinical Indication |
| Esomeprazole (40 mg) | PPI (Proton Pump Inhibitor) | Heals esophagitis, reduces heartburn, and prevents gastric ulcers. |
| Domperidone (30 mg SR) | Dopamine ($D_2$) Antagonist | Reduces nausea, prevents vomiting, and speeds up gastric emptying. |
Combined Use: It is the “Gold Standard” for Gastroesophageal Reflux Disease (GERD) accompanied by bloating, fullness, or “nausea after eating.”
Mechanism: The “One-Two Punch”
The two drugs work together to normalize the flow of the GI tract:
Acid Suppression (Esomeprazole): It technically inhibits the $H^+/K^+$-ATPase enzyme system in the stomach lining. This stops the “acid burn” that causes pain and tissue damage.
Motility Enhancement (Domperidone): It blocks $D_2$ receptors in the gut and the “Chemoreceptor Trigger Zone” (CTZ) of the brain.
The Synergy: Domperidone technically increases the pressure of the Lower Esophageal Sphincter (LES)—acting like a “valve tightener”—while simultaneously moving food out of the stomach faster. This ensures that the suppressed acid (from the Esomeprazole) stays down where it belongs.
The Pharmacist’s “Technical Warning”
The “30-Minute” Rule: To ensure the prokinetic effect is ready when food arrives, these capsules must be taken on an empty stomach, strictly 30 minutes before a meal.
Cardiac Precaution: Domperidone can technically cause QT Prolongation (heart rhythm issues) at high doses or when combined with certain antibiotics (like Erythromycin). This is a critical screening point for elderly patients.
Hormonal Changes: Chronic use of Domperidone can increase Prolactin levels, which may lead to breast tenderness or menstrual irregularities.
No Crushing: The pellets inside the capsule are Sustained-Release (SR). Chewing them causes “Dose Dumping,” which spikes blood levels and increases side-effect risks.
The Manufacturer’s Perspective: Technical & Export
From the CEO’s desk at Healthy Life Pharma / Healthy Inc:
The “SR” Pelletization USP: On your digital marketplace, highlight that your capsules use Dual-Pellet Technology.
Esomeprazole Pellets: Enteric-coated to survive stomach acid.
Domperidone Pellets: Sustained-release to provide 24-hour motility support.
The “Refractory GERD” Market: Position this FDC for the “Failed PPI” segment. Many patients on your website will be looking for something “stronger” than basic Pantoprazole. This combination is the technical answer.
Stability & Packaging: Esomeprazole is extremely moisture-sensitive. At our plant, we use Alu-Alu blistering to protect the integrity of the pellets. Standard PVC/PVDC is a technical failure for Zone IVb (tropical) exports.
Dossier Support: We provide full WHO-standard CTD/eCTD Dossiers for Esomeprazole 40 mg + Domperidone 30 mg SR to support your registration in international B2B gastro tenders.